Randomized Controlled Trial
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15837-15844
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15837
Table 2 Basic data (mean ± SD or percentage) of patients in the second study
VariableActimel groupYakult groupP value
n3030
Age (yr)69.7 ± 17.674.1 ± 17.5NS
Male gender63.3%60.0%NS
PST 0 or 170.0%51.7%NS
BMI25.9 ± 4.225.1 ± 4.1NS
Creatinine (mg/dL)1.2 ± 0.51.1 ± 0.3NS
Albumin (mg/dL)3.4 ± 0.33.3 ± 0.3NS
Diagnosis (aite of infection/aepsis)Pulmonary: 30.0% Genitourinary: 50.0% Biliary: 3.3% Sepsis: 0.0% Diverticulitis: 0.0% Dermal: 13.3% Misc.: 3.3%Pulmonary: 50.0% Genitourinary: 26.7% Biliary: 6.7% Sepsis: 3.3% Diverticulitis: 3.3% Dermal: 6.7% Misc.: 3.3%NS
AntibioticsAmpicillin: 20.0% Cefuroxime: 20.0% Ceftriaxone: 20.0% Ciprofloxacin: 0.0% Clarithromycin: 10.0% Tazobactam: 0.0% Levofloxacin: 20.0% Moxifloxacin: 0.0% Cotrimoxazole: 3.3% Penicillin: 13.3%Ampicillin: 36.7% Cefuroxime: 10.0% Ceftriaxone: 10.0% Ciprofloxacin: 3.3% Clarithromycin:16.7% Tazobactam: 10.0% Levofloxacin: 20.0% Moxifloxacin: 3.3% Cotrimoxazole: 6.7% Penicillin: 0.0%NS
Days of treatment6.0 ± 3.16.6 ± 3.7NS
Concurrent PPI treatment23.3%50.0%0.06
Antibiotic treatment in history3.3%10.0%NS